Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?

Akers, 2000, Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2, Am J Physiol Lung Cell Mol Physiol, 278, L193, 10.1152/ajplung.2000.278.1.L193 Akhurst, 2012, Targeting the TGFbeta signalling pathway in disease, Nat Rev Drug Discov, 11, 790, 10.1038/nrd3810 Akiri, 2003, Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo, Cancer Res, 63, 1657 Allen, 1999, Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis, Am J Respir Cell Mol Biol, 21, 693, 10.1165/ajrcmb.21.6.3719 Anderson, 2008, Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease, Lancet (Lond Engl), 372, 1107, 10.1016/S0140-6736(08)61452-X Anderton, 2011, Induction of heart valve lesions by small-molecule ALK5 inhibitors, Toxicol Pathol, 39, 916, 10.1177/0192623311416259 Annes, 2003, Making sense of latent TGFbeta activation, J Cell Sci, 116, 217, 10.1242/jcs.00229 Antoniou, 2013, Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer, Oncol Rep, 30, 2617, 10.3892/or.2013.2753 Arnold, 2016, Emerging Technologies for Gut Microbiome Research, Trends Microbiol, 10.1016/j.tim.2016.06.008 Bardou, 2016, Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis, Am J Respir Crit Care Med, 193, 847, 10.1164/rccm.201502-0299OC Barry-Hamilton, 2010, Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment, Nat Med, 16, 1009, 10.1038/nm.2208 Bauer, 2015, A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis, Am J Respir Cell Mol Biol, 52, 217, 10.1165/rcmb.2013-0310OC Behr, 1993, Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis, Thorax, 48, 736, 10.1136/thx.48.7.736 Belperio, 2002, Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis, Am J Respir Cell Mol Biol, 27, 419, 10.1165/rcmb.2002-0009OC Bjoraker, 1998, Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 157, 199, 10.1164/ajrccm.157.1.9704130 Black, 2016, Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis, FASEB J, 30, 2435, 10.1096/fj.201500197R Brightling, 2015, Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Respir Med, 3, 692, 10.1016/S2213-2600(15)00197-6 Busse, 1992, Eosinophils in asthma, Ann Allergy, 68, 286 Cantley, 2002, The phosphoinositide 3-kinase pathway, Sci (New York, N.Y.), 296, 1655, 10.1126/science.296.5573.1655 Clarke, 2013, Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes, Fibrogenesis Tissue Repair, 6, 10.1186/1755-1536-6-20 Collard, 2016, Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report, Am J Respir Crit Care Med, 10.1164/rccm.201604-0801CI Corren, 2011, Lebrikizumab treatment in adults with asthma, N Engl J Med, 365, 1088, 10.1056/NEJMoa1106469 Daniels, 2010, Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results, Am J Respir Crit Care Med, 181, 604, 10.1164/rccm.200906-0964OC Darby, 2014, Fibroblasts and myofibroblasts in wound healing, Clin Cosmet Investig Dermatol, 7, 301 Decologne, 2007, TGF-beta1 induces progressive pleural scarring and subpleural fibrosis, J Immunol, 179, 6043, 10.4049/jimmunol.179.9.6043 Demedts, 2005, High-dose acetylcysteine in idiopathic pulmonary fibrosis, N Engl J Med, 353, 2229, 10.1056/NEJMoa042976 Depianto, 2015, Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis, Thorax, 70, 48, 10.1136/thoraxjnl-2013-204596 Donahoe, 2015, Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis, PloS one, 10, 10.1371/journal.pone.0127771 Du Bois, 2011, Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 184, 459, 10.1164/rccm.201011-1790OC Egger, 2013, Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology, PloS one, 8, 10.1371/journal.pone.0063432 Fingerlin, 2013, Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis, Nat Genet, 45, 613, 10.1038/ng.2609 Flood-Page, 2003, Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway, Am J Respir Crit Care Med, 167, 199, 10.1164/rccm.200208-789OC Flood-Page, 2007, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma, Am J Respir Crit Care Med, 176, 1062, 10.1164/rccm.200701-085OC Foster, 1996, Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model, J Exp Med, 183, 195, 10.1084/jem.183.1.195 Francois, 2015, B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis, J Autoimmun, 56, 1, 10.1016/j.jaut.2014.08.003 Frazier, 2007, Inhibition of ALK5 signaling induces physeal dysplasia in rats, Toxicol Pathol, 35, 284, 10.1080/01926230701198469 Fregonese, 2015, The future of the development of medicines in idiopathic pulmonary fibrosis, BMC medicine, 13, 10.1186/s12916-015-0480-7 Giannandrea, 2014, Diverse functions of matrix metalloproteinases during fibrosis, Dis Model Mech, 7, 193, 10.1242/dmm.012062 Gilani, 2010, CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis, PloS one, 5, 10.1371/journal.pone.0008959 Goodwin, 2016, Molecular endotyping of pulmonary fibrosis, Chest, 149, 228, 10.1378/chest.15-1511 Gordon, 2003, Alternative activation of macrophages, Nat Rev Immunol, 3, 23, 10.1038/nri978 Gribbin, 2009, Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis, Respir Med, 103, 927, 10.1016/j.rmed.2008.11.001 Grimminger, 2010, Targeting non-malignant disorders with tyrosine kinase inhibitors, Nat Rev Drug Discov, 9, 956, 10.1038/nrd3297 Haldar, 2009, Mepolizumab and exacerbations of refractory eosinophilic asthma, N Engl J Med, 360, 973, 10.1056/NEJMoa0808991 Hamelmann, 1999, Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness, Am J Respir Crit Care Med, 160, 934, 10.1164/ajrccm.160.3.9806029 Hams, 2014, IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis, Proc Natl Acad Sci U S A, 111, 367, 10.1073/pnas.1315854111 Hanania, 2015, Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies, Thorax, 70, 748, 10.1136/thoraxjnl-2014-206719 Hancock, 1998, Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung, Am J Respir Cell Mol Biol, 18, 60, 10.1165/ajrcmb.18.1.2627 Hasegawa, 1997, Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis, J Rheumatol, 24, 328 Hasegawa, 2003, Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma, Dermatol (Basel, Switz), 207, 141, 10.1159/000071783 Henderson, 2008, Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis, Am J Pathol, 172, 288, 10.2353/ajpath.2008.070726 Henderson, 2006, Galectin-3 regulates myofibroblast activation and hepatic fibrosis, Proc Natl Acad Sci U S A, 103, 5060, 10.1073/pnas.0511167103 Henry, 2002, Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF, Eur Respir J, 20, 1220, 10.1183/09031936.02.00022302 Herazo-Maya, 2013, Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis, Sci Transl Med, 5, 10.1126/scitranslmed.3005964 Horan, 2008, Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation, Am J Respir Crit Care Med, 177, 56, 10.1164/rccm.200706-805OC Hostettler, 2014, Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis, Respir Res, 15, 10.1186/s12931-014-0157-3 Houghton, 2015, Matrix metalloproteinases in destructive lung disease, Matrix Biol., 44-46, 167, 10.1016/j.matbio.2015.02.002 Howell, 2005, Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis, Am J Pathol, 166, 1353, 10.1016/S0002-9440(10)62354-1 Huang, 2013, Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice, Am J Respir Cell Mol Biol, 49, 912, 10.1165/rcmb.2013-0070OC Hubbard, 1996, Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis, Lancet (Lond Engl), 347, 284, 10.1016/S0140-6736(96)90465-1 Humbles, 2004, A critical role for eosinophils in allergic airways remodeling, Sci (New York, N.Y.), 305, 1776, 10.1126/science.1100283 Idiopathic Pulmonary Fibrosis Clinical Research Network, 2014, Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis, N Engl J Med, 370, 2093, 10.1056/NEJMoa1401739 Idiopathic Pulmonary Fibrosis Clinical Research Network, 2012, Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis, N Engl J Med, 366, 1968, 10.1056/NEJMoa1113354 Iyer, 1999, Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis, J Pharmacol Exp Ther, 291, 367 Izuhara, 2016, Roles of periostin in respiratory disorders, Am J Respir Crit Care Med, 193, 949, 10.1164/rccm.201510-2032PP Jakubzick, 2004, Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis, Immunol Res, 30, 339, 10.1385/IR:30:3:339 Jenkins, 2015, Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study, Lancet Respir. Med., 3, 462, 10.1016/S2213-2600(15)00048-X Kahloon, 2013, Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses, Am J Respir Crit Care Med, 187, 768, 10.1164/rccm.201203-0506OC Kannengiesser, 2015, Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis, Eur Respir J, 46, 474, 10.1183/09031936.00040115 Karimi-Shah, 2015, Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib, N Engl J Med, 372, 1189, 10.1056/NEJMp1500526 Kennedy, 2015, Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis, Sarcoidosis Vasc Diffuse Lung Dis, 32, 228 Kim, 2006, Classification and natural history of the idiopathic interstitial pneumonias, Proc Am Thorac Soc, 3, 285, 10.1513/pats.200601-005TK King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, 370, 2083, 10.1056/NEJMoa1402582 King, 2001, Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model, Am J Respir Crit Care Med, 164, 1171, 10.1164/ajrccm.164.7.2003140 Kolodsick, 2004, Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts, J Immunol, 172, 4068, 10.4049/jimmunol.172.7.4068 Konishi, 2009, Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 180, 167, 10.1164/rccm.200810-1596OC Kral, 2016, Sustained PI3K activation exacerbates BLM-induced lung fibrosis via activation of pro-inflammatory and pro-fibrotic pathways, Sci Rep, 6, 23034, 10.1038/srep23034 Kropski, 2015, The genetic basis of idiopathic pulmonary fibrosis, Eur Respir J, 45, 1717, 10.1183/09031936.00163814 Kubo, 2005, Anticoagulant therapy for idiopathic pulmonary fibrosis, Chest, 128, 1475, 10.1378/chest.128.3.1475 Kuhn, 1989, An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis, Am Rev Respir Dis, 140, 1693, 10.1164/ajrccm/140.6.1693 Labiris, 2003, Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications, Br J Clin Pharmacol, 56, 588, 10.1046/j.1365-2125.2003.01892.x Lawson, 2006, The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?, Proc Am Thorac Soc, 3, 345, 10.1513/pats.200512-137TK Leask, 2009, Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?, J Cell Commun Signal, 3, 89, 10.1007/s12079-009-0037-7 Leckie, 2000, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response, Lancet (Lond Engl), 356, 2144, 10.1016/S0140-6736(00)03496-6 Lehtonen, 2016, Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis, Respir Res, 17, 10.1186/s12931-016-0328-5 Ley, 2014, Molecular biomarkers in idiopathic pulmonary fibrosis, Am J Physiol Lung Cell Mol Physiol, 307, L681, 10.1152/ajplung.00014.2014 Ley, 2011, Clinical course and prediction of survival in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 183, 431, 10.1164/rccm.201006-0894CI Ley, 2012, A multidimensional index and staging system for idiopathic pulmonary fibrosis, Ann Intern Med, 156, 684, 10.7326/0003-4819-156-10-201205150-00004 Liu, 2004, Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6, J. Immunol., 173, 3425, 10.4049/jimmunol.173.5.3425 Liu, 2011, CCN2 is required for bleomycin-induced skin fibrosis in mice, Arthritis Rheum, 63, 239, 10.1002/art.30074 Liu, 2013, Telomerase and telomere length in pulmonary fibrosis, Am J Respir Cell Mol Biol, 49, 260, 10.1165/rcmb.2012-0514OC Luzina, 2008, Roles of T lymphocytes in pulmonary fibrosis, J Leukoc Biol, 83, 237, 10.1189/jlb.0707504 Mackinnon, 2012, Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3, Am J Respir Crit Care Med, 185, 537, 10.1164/rccm.201106-0965OC Maher, 2007, Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?, Eur Respir J, 30, 835, 10.1183/09031936.00069307 Malouf, 2011, An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis, Respirology (Carlton, Vic.), 16, 776, 10.1111/j.1440-1843.2011.01955.x Mapel, 1996, Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future, Chest, 110, 1058, 10.1378/chest.110.4.1058 Marchal-Somme, 2007, Dendritic cells accumulate in human fibrotic interstitial lung disease, Am J Respir Crit Care Med, 176, 1007, 10.1164/rccm.200609-1347OC Marchal-Somme, 2006, Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis, J Immunol, 176, 5735, 10.4049/jimmunol.176.10.5735 Marshall, 2000, Adult familial cryptogenic fibrosing alveolitis in the United Kingdom, Thorax, 55, 143, 10.1136/thorax.55.2.143 Mercer, 2016, Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF, Thorax, 71, 701, 10.1136/thoraxjnl-2015-207429 Molyneaux, 2014, The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 190, 906, 10.1164/rccm.201403-0541OC Moore, 2005, CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury, Am J Pathol, 166, 675, 10.1016/S0002-9440(10)62289-4 Mu, 2002, The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1, J Cell Biol, 157, 493, 10.1083/jcb.200109100 Murray, 2008, Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2, Int J Biochem Cell Biol, 40, 2174, 10.1016/j.biocel.2008.02.016 Murray, 2011, TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P, Int J Biochem Cell Biol, 43, 154, 10.1016/j.biocel.2010.10.013 Murray, 2010, Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages, PloS one, 5, 10.1371/journal.pone.0009683 Murray, 2014, Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model, Am J Respir Cell Mol Biol, 50, 985, 10.1165/rcmb.2013-0342OC Myers, 1988, Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia, Chest, 94, 1309, 10.1378/chest.94.6.1309 Naik, 2012, Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis, Am J Physiol Lung Cell Mol Physiol, 303, L1046, 10.1152/ajplung.00139.2012 Nair, 2009, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, N Engl J Med, 360, 985, 10.1056/NEJMoa0805435 Nho, 2006, PTEN regulates fibroblast elimination during collagen matrix contraction, J Biol Chem, 281, 33291, 10.1074/jbc.M606450200 Noble, 2011, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet (Lond Engl), 377, 1760, 10.1016/S0140-6736(11)60405-4 Noth, 2013, Reply: a placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis: a hidden subgroup?, Am J Respir Crit Care Med, 187, 1030, 10.1164/rccm.201211-2060LE Noth, 2013, Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study, Lancet Respir Med, 1, 309, 10.1016/S2213-2600(13)70045-6 Ogura, 2015, Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis, Eur Respir J, 45, 1382, 10.1183/09031936.00198013 Oh, 2011, Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice, J Exp Med, 208, 1707, 10.1084/jem.20101457 Okamoto, 2011, Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias, Eur Respir J, 37, 1119, 10.1183/09031936.00059810 Oku, 2008, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis, Eur J Pharmacol, 590, 400, 10.1016/j.ejphar.2008.06.046 Oldham, 2015, TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 192, 1475, 10.1164/rccm.201505-1010OC Olsen, 2014, Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules, Am J Respir Cell Mol Biol, 50, 737, 10.1165/rcmb.2013-0092OC Olson, 2009, Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter, Chest, 136, 16, 10.1378/chest.08-0703 Park, 2009, Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function, J Korean Med Sci, 24, 614, 10.3346/jkms.2009.24.4.614 Peljto, 2013, Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis, JAMA, 309, 2232, 10.1001/jama.2013.5827 Peng, 2013, Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease, PloS one, 8, 10.1371/journal.pone.0059348 Pilling, 2003, Inhibition of fibrocyte differentiation by serum amyloid P, J Immunol, 171, 5537, 10.4049/jimmunol.171.10.5537 Pilling, 2007, Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P, J Immunol, 179, 4035, 10.4049/jimmunol.179.6.4035 Prasse, 2006, A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18, Am J Respir Crit Care Med, 173, 781, 10.1164/rccm.200509-1518OC Raghu, 2015, CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab, Eur Respir J, 46, 1740, 10.1183/13993003.01558-2014 Raghu, 2015, An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline, Am J Respir Crit Care Med, 192, e3, 10.1164/rccm.201506-1063ST Raghu, 2008, Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial, Am J Respir Crit Care Med, 178, 948, 10.1164/rccm.200709-1446OC Raghu, 2012, Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials, Am J Respir Crit Care Med, 185, 1044, 10.1164/rccm.201201-0006PP Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, 183, 788, 10.1164/rccm.2009-040GL Raghu, 2006, High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis, Eur Respir J, 27, 136, 10.1183/09031936.06.00037005 Raghu, 2016, FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF, Eur Respir J, 47, 1481, 10.1183/13993003.01030-2015 Rangarajan, 2016, Novel mechanisms for the antifibrotic action of nintedanib, Am J Respir Cell Mol Biol, 54, 51, 10.1165/rcmb.2014-0445OC Rice, 2015, Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, J Clin Invest, 125, 2795, 10.1172/JCI77958 Richards, 2012, Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 185, 67, 10.1164/rccm.201101-0058OC Rosas, 2008, MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis, PLoS Med, 5, e93, 10.1371/journal.pmed.0050093 Rucker, 1978, Cross-linking amino acids in collagen and elastin, Am J Clin Nutr, 31, 1221, 10.1093/ajcn/31.7.1221 Ryerson, 2014, Predicting survival across chronic interstitial lung disease: the ILD-GAP model, Chest, 145, 723, 10.1378/chest.13-1474 Saito, 2003, Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro, Int Arch Allergy Immunol, 132, 168, 10.1159/000073718 Sakai, 2013, Fibrosis of two: epithelial cell-fibroblast interactions in pulmonary fibrosis, Biochim Biophys Acta, 1832, 911, 10.1016/j.bbadis.2013.03.001 Schupp, 2015, Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis, PloS one, 10, 10.1371/journal.pone.0116775 Scotton, 2007, Molecular targets in pulmonary fibrosis: the myofibroblast in focus, Chest, 132, 1311, 10.1378/chest.06-2568 Seibold, 2011, A common MUC5B promoter polymorphism and pulmonary fibrosis, N Engl J Med, 364, 1503, 10.1056/NEJMoa1013660 Shi, 2011, Latent TGF-beta structure and activation, Nature, 474, 343, 10.1038/nature10152 Shulgina, 2013, Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial, Thorax, 68, 155, 10.1136/thoraxjnl-2012-202403 Sonnylal, 2010, Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis, Arthritis Rheum, 62, 1523, 10.1002/art.27382 Stuart, 2015, Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening, Nat Genet, 47, 512, 10.1038/ng.3278 Tager, 2012, Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis, Am J Respir Cell Mol Biol, 47, 563, 10.1165/rcmb.2012-0235ED Tager, 2008, The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak, Nat Med, 14, 45, 10.1038/nm1685 Taille, 2011, Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 183, 759, 10.1164/rccm.201001-0076OC Tang, 2006, Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis, Lung Cancer (Amsterdam, Neth), 51, 181, 10.1016/j.lungcan.2005.10.003 Taskar, 2006, Is idiopathic pulmonary fibrosis an environmental disease?, Proc Am Thorac Soc, 3, 293, 10.1513/pats.200512-131TK Tatler, 2012, TGF-beta activation and lung fibrosis, Proc Am Thorac Soc, 9, 130, 10.1513/pats.201201-003AW Tatler, 2015, Reducing affinity of alphavbeta8 interactions with latent TGFbeta: dialling down fibrosis, Ann Transl Med, 3, S31 Thomson, 2012, Lebrikizumab in the personalized management of asthma, Biologics, 6, 329 Trivedi, 2012, Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice, Nanotechnology, 23, 10.1088/0957-4484/23/50/505101 Vadasz, 2005, Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2, J Hepatol, 43, 499, 10.1016/j.jhep.2005.02.052 Van Moorsel, 2010, Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort, Am J Respir Crit Care Med, 182, 1419, 10.1164/rccm.200906-0953OC Vuga, 2014, C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 189, 966, 10.1164/rccm.201309-1592OC Walker, 1994, Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia, Am J Respir Crit Care Med, 150, 1038, 10.1164/ajrccm.150.4.7921434 Watterson, 2007, Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing, Wound Repair Regen, 15, 607, 10.1111/j.1524-475X.2007.00292.x Wells, 2003, Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography, Am J Respir Crit Care Med, 167, 962, 10.1164/rccm.2111053 Wells, 1995, Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium, Eur Respir J, 8, 266, 10.1183/09031936.95.08020266 Wilkes, 2015, Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis, Eur Respir J, 45, 1393, 10.1183/09031936.00105314 Wilson, 2009, Pulmonary fibrosis: pathogenesis, etiology and regulation, Mucosal Immunol, 2, 103, 10.1038/mi.2008.85 Wollin, 2014, Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis, J Pharmacol Exp Ther, 349, 209, 10.1124/jpet.113.208223 Wollin, 2015, Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, Eur Respir J, 45, 1434, 10.1183/09031936.00174914 Wuyts, 2014, Combination therapy: the future of management for idiopathic pulmonary fibrosis?, Lancet Respir Med, 2, 933, 10.1016/S2213-2600(14)70232-2 Wygrecka, 2013, Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-alpha/Raf-1/p44/42 signaling pathway, Am J Pathol, 182, 2094, 10.1016/j.ajpath.2013.02.013 Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034 Xia, 2014, Identification of a cell-of-origin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis, Am J Pathol, 184, 1369, 10.1016/j.ajpath.2014.01.012 Xia, 2010, Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis, Am J Pathol, 176, 2626, 10.2353/ajpath.2010.091117 Xu, 2009, Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q), Am J Pathol, 174, 1264, 10.2353/ajpath.2009.080160 Xue, 2013, Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients, J. Immunol., 191, 2089, 10.4049/jimmunol.1203476 Yamauchi, 2008, Lysine hydroxylation and cross-linking of collagen, Methods Mol Biol (Clifton, N.J.), 446, 95, 10.1007/978-1-60327-084-7_7 Zhu, 1999, Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J Clin Invest, 103, 779, 10.1172/JCI5909